polycarbophil (OTC)

Brand and Other Names:FiberCon, Fiber Lax, more...Equalactin, FiberNorm, Mitrolan
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 625mg

tablet, chewable

  • 625mg
more...

Constipation

1250 mg with 8 oz of water PO qday to q6hr; not to exceed 6 g/day

Dosage Forms & Strengths

tablet

  • 625mg

tablet, chewable

  • 625mg
more...

Constipation

<6 years:  Administer under physician supervision; 625 mg with 8 oz of water PO qDay or q12hr; not to exceed 1.25 g/day

>6-12 years: Swallow 1 tab qDay or q6hr

>12 years: 1250 mg with 8 oz of water PO q6hr; not to exceed 6 g/day

Constipation

1250 mg with 8 oz of water PO qday to q6hr; not to exceed 6 g/day

Next:

Interactions

Interaction Checker

and polycarbophil

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Abdominal fullness

            Flatulence

            Vomiting

            Stomach cramps

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Bowel obstruction, appendicitis, dysphagia, fecal impaction, rectal bleeding

            Cautions

            Should be taken with enough fluid

            If tetracycline is concurrently administered, take tetracycline 1 hr after or 2 hr before polycarbophil

            Use in children <6 years

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: NA; not absorbed; safe to be administered in pregnancy

            Lactation: No data in nursing women; not absorbed and should be safe to use in nursing women

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Bulk producing laxative that restores normal moisture level

            Pharmacokinetics

            Absorption: Minimal systemic absorption

            Onset: 12-72 hr

            Metabolism: Metabolically inert

            Excretion: Feces

            Previous
            Next:

            Images

            Previous
            Next: